Santen Pharmaceutical Co., Ltd.

Other

Eisai Company, Limited

Shiro Mita

Yoichi Kawashima

Takakazu Morita

Hiroshi Suhara

Masakazu Ban

Masato Horiuchi

Tadashi Iso

Youichi Kawashima

Ken-ichi Fujimura

Hiroshi Kuriyama

Naruhiro Ishida

Kousaku Okubo

Katsuhiko Nakata

Mitsushi Hikida

Tsutomu Suzuki

Kiyoshi Matsuno

Hidehito Matsuoka

Masahiro Okamoto

Masataka Morishita

Koji Yoneda

Nobuharu Kato

Michel F Degre

Eiichi Shirasawa

Polypeptide having water channel activity and DNA sequence

Urea derivatives useful as synthetic intermediates

N-Substituted-N&prime;-substituted urea derivatives represented by the following formula, analogs thereof or pharmaceutically acceptable salts thereof are herein provided. These compounds show a TNF-&agr; production inhibitory activity.

N-substituted-N&prime;-substituted urea derivatives and pharmaceutical compositions containing the derivatives

N-substituted-N&prime;-substituted urea derivatives and the use thereof as TNF-&agr; production inhibitory agents

A method for preventing or treating drug dependence comprising administering to a human in need thereof a pharmaceutically effective amount of a 1,4-(diphenylalkyl)piperazine compound represented by the following formula &lsqb;I&rsqb; or a pharmaceutically acceptable salt thereof, wherein R is lower alkoxy; R is lower alkoxy; A is lower alkylene and B is lower alkylene;

Therapeutic agents for drug dependence

Urea derivatives and pharmaceutical compositions thereof

A method for inhibiting angiogenesis comprising administering to a patient (mammal, such as a human) in need thereof, a pharmaceutically effective amount of an angiogenesis inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier. The method of treatment may be used to treat diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma.

Angiogenesis inhibitors

An object of the present invention is to provide novel urea derivatives which have TNF-&agr; production inhibitory effects and are useful as therapeutic agents for various diseases, particularly as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. The urea derivatives according to the present invention are compounds represented by the formula &lsqb;I&rsqb; and salts thereof. In the formula, R is H, alkyl, phenyl or a group of the formula &lsqb;`I&rsqb;; R is H, alkyl, carboxyl or ester thereof or the like; R and R are each H, alkyl, cycloalkyl or the like; R is H, alkyl, hydroxy or the like; R is a nitrogen aromatic heterocycle; and A and A are alkylene.

Urea derivatives having nitrogen aromatic heterocycle

A therapeutic agent for glaucoma comprises (&plus;)-(R)-3,4-Dihydro-2-&lsqb;5-methoxy-2-&lsqb;3-&lsqb;N-methyl-N-&lsqb;2-&lsqb;(3,4-methylenedioxy) phenoxy&rsqb;ethyl&rsqb;amino&rsqb;propoxy&rsqb;phenyl&rsqb;-4-methyl-3-oxo-2H-1,4-benzothiazine or its salt as active ingredient and pharmaceutically acceptable excipients. The therapeutic agent lowers the intraocular pressure upon topical or systemic administration.

Therapeutic agent for glaucoma

The present invention relates to leukotriene A,hydrolase inhibitors containing compounds represented by the formula &lsqb;I&rsqb; or salts thereof as active ingredients,

Leukotriene A4 hydrolase inhibitors

A method for the healing of wounds caused by corneal injury, which includes administering to a mammalian patient in need thereof an effective wound healing amount of lactoferrin, lactoperoxidase or a combination of lactoferrin and lactoperoxidase as active ingredients, either alone or in admixture with at least one excipient.

Method for the healing of wounds caused by corneal injury

Substituted butaneolides and butane lactams, and pharmaceutical use

A compound of the formula [I]. ##STR1## The compounds of this invention has excellent thymulin-line activities and expected to be useful for treatment of various diseases such as immunodeficiency and autoimmune diseases.

Bicyclic compounds

This invention relates to cysteine derivatives of the formula[I] and salts thereof. ##STR1## The compounds of this invention are useful for immunomodulator and treatment of liver disorder.

Cysteine derivatives

Growing community of inventors

Ashiya, Japan

Shiro Mita